Clinuvel Pharmaceuticals Limited
ASX: CUV
Clinuvel’s revenue rose 10% on SCENESSE growth.
(Source: TradingView) 3-Month Performance Profile of CUV on a DTF compared to S&P/ASX 200 (XJO).
Clinuvel reported a total revenue of $105.3 million in FY25, marking a 7.8% YoY increase, supported by continued commercial success of SCENESSE in EPP, which remains the company’s key growth driver. Net pro
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
